+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Injectables Market by Dimension Query Chat Segmentation - Global Forecast to 2030- Product Image
Generic Injectables Market by Dimension Query Chat Segmentation - Global Forecast to 2030- Product Image
Sale

Generic Injectables Market by Dimension Query Chat Segmentation - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887534
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The generic injectables market is experiencing accelerated evolution as healthcare providers, regulators, and industry stakeholders prioritize accessibility, efficiency, and innovation across treatment landscapes. Heightened demand for cost-effective and high-quality injectables, coupled with the drive for operational resilience, is defining new benchmarks and creating opportunities for decisive market leadership.

Market Snapshot: Generic Injectables Market Size & Growth

The Generic Injectables Market grew from USD 36.58 billion in 2024 to USD 40.64 billion in 2025. It is expected to continue growing at a CAGR of 10.69%, reaching USD 67.30 billion by 2030. With robust momentum, this sector is poised for significant advancement as buyers, manufacturers, and policymakers respond to shifting clinical and commercial imperatives. The trajectory underscores expanding global reliance on generic injectables to support diverse healthcare delivery models and sustainability objectives.

Scope & Segmentation: Strategic Coverage of the Generic Injectables Market

  • Distribution Channels: Direct tender, hospital pharmacy distribution, online channels (B2C platforms, e-pharmacies), and retail distribution support varied procurement strategies and workflow optimizations.
  • Dosage Forms: Emulsions, lyophilized powders, solutions, and suspensions address unique stability, formulation, and administration challenges.
  • Drug Classes: Analgesics, anesthetics, cardiovascular agents, a wide antibiotic range (aminoglycosides, beta-lactams, glycopeptides), and oncology agents (cytotoxics, monoclonal antibodies) reflect the broad therapeutic applications served.
  • End Users: Ambulatory surgical centers, community and specialty clinics, hospital pharmacies, and retail pharmacies meet diverse clinical and inventory requirements.
  • Large Volume Parenteral Options: Delivered via bags or bottles to support high-throughput clinical settings.
  • Molecules Profiled: Cefuroxime, fentanyl, meropenem, oxaliplatin, vancomycin illustrate patent landscapes and specialized supply chains.
  • Packaging Types: Ampoules, cartridges, pre-filled syringes (safety and standard), and vials optimize safety and user convenience.
  • Product Types: Ampoule, pre-filled syringes (safety and standard), vial options to support different clinical protocols.
  • Routes of Administration: Intramuscular, intravenous, and subcutaneous support broad care delivery requirements.
  • Therapeutic Applications: Cover anesthesia, anti-infective regimens, cardiovascular, oncology (both cytotoxic and targeted therapies), and comprehensive pain management strategies including both opioid and non-opioid options.
  • Regions Covered: Americas (with detailed state-level coverage in the US, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., UK, Germany, France, Russia, UAE, South Africa), Asia-Pacific (e.g., China, India, Japan, Australia, South Korea).
  • Major Companies Profiled: Fresenius Kabi AG, Baxter International Inc., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Hikma Pharmaceuticals PLC, Viatris Inc., Amneal Pharmaceuticals Inc., Aspen Pharmacare Holdings Limited, Recipharm AB.

Key Takeaways: Strategic Insights for Decision-Makers

  • Stakeholders are adopting robust procurement strategies to balance cost-efficiency with clinical quality, reflecting changing reimbursement and value-based care models.
  • Manufacturers are investing in continuous manufacturing platforms and digital traceability technologies, enhancing agility, compliance, and risk mitigation across supply chains.
  • Competition from biosimilar alternatives and complex generics introduces new pressures but simultaneously encourages innovation in formulation and delivery mechanisms.
  • Providers and payers increasingly demand transparent sourcing and documentation, fostering emerging investment in supply chain digitization and cloud-based quality management.
  • Regional dynamics—from North American regulatory stringency to Asia-Pacific’s scale efficiencies—necessitate region-specific entry and expansion strategies for market participants.

Tariff Impact: 2025 US Tariff Changes and Strategic Adjustments

  • Imposed US tariffs in 2025 are elevating operational and sourcing costs for key raw materials and specialized components, intensifying margin pressures on manufacturers.
  • Strategic pivots toward domestic production and supplier diversification are underway, especially among firms aiming to minimize exposure to trade policy volatility.
  • Evolving contract structures reflect a shift toward flexible pricing and collaborative scenario planning between distributors and healthcare providers to safeguard economic sustainability.

Methodology & Data Sources

This report integrates in-depth interviews with global industry opinion leaders and procurement specialists, validated with regulatory databases, peer-reviewed literature, and government sources. Commercial sales, trade flow statistics, and multi-source cross-referencing reinforce analytical reliability and actionable guidance.

Why This Report Matters

  • Enables senior leaders to identify growth opportunities and respond to regulatory changes with real-time, segmented insights.
  • Supports strategic decisions on technology adoption, procurement resilience, and regional market entry by distilling complex, multidimensional data into clear recommendations.

Conclusion

The generic injectables sector is shaped by innovation, regulatory adaptation, and dynamic global trade pressures. This report provides a comprehensive framework to inform strategy, identify risks, and capture value in a rapidly evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Generic Injectables Market, by Dimension Query Chat Segmentation
8.1. Introduction
8.2. Distribution Channel
8.2.1. Direct Tender
8.2.2. Hospital Pharmacy Distribution
8.2.3. Online Distribution
8.2.3.1. B2C Platforms
8.2.3.2. E-Pharmacies
8.2.4. Retail Distribution
8.3. Dosage Form
8.3.1. Emulsion
8.3.2. Lyophilized Powder
8.3.3. Solution
8.3.4. Suspension
8.4. Drug Class
8.4.1. Analgesics
8.4.2. Anesthetics
8.4.3. Antibiotics
8.4.3.1. Aminoglycosides
8.4.3.2. Beta-Lactams
8.4.3.3. Glycopeptides
8.4.4. Cardiovascular Agents
8.4.5. Oncology Agents
8.4.5.1. Cytotoxics
8.4.5.2. Monoclonal Antibodies
8.5. End User
8.5.1. Ambulatory Surgical Centers
8.5.2. Clinics
8.5.2.1. Community Clinics
8.5.2.2. Specialty Clinics
8.5.3. Hospital Pharmacies
8.5.4. Retail Pharmacies
8.6. Large Volume Parenteral
8.6.1. Bag
8.6.2. Bottle
8.7. Molecule
8.7.1. Cefuroxime
8.7.2. Fentanyl
8.7.3. Meropenem
8.7.4. Oxaliplatin
8.7.5. Vancomycin
8.8. Packaging Type
8.8.1. Ampoules
8.8.2. Cartridges
8.8.3. Pre-Filled Syringes
8.8.3.1. Safety Syringes
8.8.3.2. Standard Syringes
8.8.4. Vials
8.9. Product Type
8.9.1. Ampoule
8.9.2. Pre-Filled Syringe
8.9.2.1. Safety Syringe
8.9.2.2. Standard Syringe
8.9.3. Vial
8.10. Route of Administration
8.10.1. Intramuscular
8.10.2. Intravenous
8.10.3. Subcutaneous
8.11. Therapeutic Application
8.11.1. Anesthesia
8.11.2. Anti-Infective
8.11.2.1. Antibiotics
8.11.2.2. Antivirals
8.11.3. Cardiovascular
8.11.4. Oncology
8.11.4.1. Cytotoxic Agents
8.11.4.2. Targeted Therapies
8.11.5. Pain Management
8.11.5.1. Non-Opioids
8.11.5.2. Opioids
9. Americas Generic Injectables Market
9.1. Introduction
9.2. United States
9.3. Canada
9.4. Mexico
9.5. Brazil
9.6. Argentina
10. Europe, Middle East & Africa Generic Injectables Market
10.1. Introduction
10.2. United Kingdom
10.3. Germany
10.4. France
10.5. Russia
10.6. Italy
10.7. Spain
10.8. United Arab Emirates
10.9. Saudi Arabia
10.10. South Africa
10.11. Denmark
10.12. Netherlands
10.13. Qatar
10.14. Finland
10.15. Sweden
10.16. Nigeria
10.17. Egypt
10.18. Turkey
10.19. Israel
10.20. Norway
10.21. Poland
10.22. Switzerland
11. Asia-Pacific Generic Injectables Market
11.1. Introduction
11.2. China
11.3. India
11.4. Japan
11.5. Australia
11.6. South Korea
11.7. Indonesia
11.8. Thailand
11.9. Philippines
11.10. Malaysia
11.11. Singapore
11.12. Vietnam
11.13. Taiwan
12. Competitive Landscape
12.1. Market Share Analysis, 2024
12.2. FPNV Positioning Matrix, 2024
12.3. Competitive Analysis
12.3.1. Fresenius Kabi AG
12.3.2. Baxter International Inc.
12.3.3. Pfizer Inc.
12.3.4. Sandoz International GmbH
12.3.5. Teva Pharmaceutical Industries Limited
12.3.6. Hikma Pharmaceuticals PLC
12.3.7. Viatris Inc.
12.3.8. Amneal Pharmaceuticals Inc.
12.3.9. Aspen Pharmacare Holdings Limited
12.3.10. Recipharm AB
13. ResearchAI
14. ResearchStatistics
15. ResearchContacts
16. ResearchArticles
17. Appendix
List of Figures
FIGURE 1. GENERIC INJECTABLES MARKET MULTI-CURRENCY
FIGURE 2. GENERIC INJECTABLES MARKET MULTI-LANGUAGE
FIGURE 3. GENERIC INJECTABLES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 10. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 12. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 18. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY B2C PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY E-PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY EMULSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOTOXICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY END USER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BAG, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BOTTLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CEFUROXIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY OXALIPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMPOULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY STANDARD SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMPOULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SAFETY SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY STANDARD SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANESTHESIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 136. CANADA GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 137. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. CANADA GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. CANADA GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 140. CANADA GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. CANADA GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 142. CANADA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 143. CANADA GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. CANADA GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 145. CANADA GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 146. CANADA GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 147. CANADA GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 148. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 149. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 151. CANADA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. CANADA GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. CANADA GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 154. CANADA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 155. CANADA GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 156. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 157. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 159. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 160. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 162. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 163. MEXICO GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. MEXICO GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 166. MEXICO GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 167. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 168. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. MEXICO GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 174. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 175. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 257. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 258. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 260. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 263. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. GERMANY GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 266. GERMANY GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 267. GERMANY GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 268. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 269. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 270. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 272. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. GERMANY GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 275. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 276. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 277. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 278. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 280. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 281. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. FRANCE GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. FRANCE GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 287. FRANCE GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 288. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 289. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 290. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 292. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. FRANCE GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 295. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 296. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 308. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 309. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 310. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 312. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 314. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ANTI-INFECTIVE, 2018-2030 (USD MILLION)
TABLE 315. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 316. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 317. ITALY GENERIC INJECTABLES MARKET SIZE, BY DIMENSION QUERY CHAT SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 318. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. ITALY GENERIC INJECTABLES MARKET SIZE, BY ONLINE DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 320. ITALY GENERIC INJECTABLES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 321. ITALY GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. ITALY GENERIC INJECTABLES MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 323. ITALY GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2030 (USD MILLION)
TABLE 324. ITALY GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. ITALY GENERIC INJECTABLES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 326. ITALY GENERIC INJECTABLES MARKET SIZE, BY LARGE VOLUME PARENTERAL, 2018-2030 (USD MILLION)
TABLE 327. ITALY GENERIC INJECTABLES MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
TABLE 328. ITALY GENERIC INJECTABLES MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 329. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, 2018-2030 (USD MILLION)
TABLE 330. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 331. ITAL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Generic Injectables market report include:
  • Fresenius Kabi AG
  • Baxter International Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Limited
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Amneal Pharmaceuticals Inc.
  • Aspen Pharmacare Holdings Limited
  • Recipharm AB

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 40.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 67.3 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Generic Injectables - Global Strategic Business Report - Product Image

Generic Injectables - Global Strategic Business Report

  • Report
  • 602 Pages
  • Global
From
Generic Injectables Market Report 2025-2033 - Product Image

Generic Injectables Market Report 2025-2033

  • Report
  • 125 Pages
  • Global
From
Generic Injectables Market Report 2025 - Product Image

Generic Injectables Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Generic Oncology Sterile Injectable Market Report 2025 - Product Image

Generic Oncology Sterile Injectable Market Report 2025

  • Report
  • 200 Pages
  • Global
From
HIV Drugs and Injectables Market Report 2024-2034 - Product Image

HIV Drugs and Injectables Market Report 2024-2034

  • Report
  • 288 Pages
  • Global
From

About the Generic Injectable Market

The Generic Injectable market is a segment of the drug delivery industry that focuses on the production and distribution of generic injectable drugs. These drugs are typically administered via injection and are used to treat a variety of medical conditions. Generic injectables are typically cheaper than their branded counterparts, making them a popular choice for patients and healthcare providers alike. Generic injectables are typically produced in bulk and then packaged and distributed to pharmacies and hospitals. The production process involves the use of sterile manufacturing techniques and quality control measures to ensure the safety and efficacy of the drugs. Generic injectables are an important part of the drug delivery industry, as they provide an affordable and effective way to treat a variety of medical conditions. Some companies in the Generic Injectable market include Hospira, Mylan, Teva Pharmaceuticals, Sandoz, and Fresenius Kabi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.